gms | German Medical Science

German Congress of Orthopaedics and Traumatology (DKOU 2024)

22. - 25.10.2024, Berlin

Galleria mellonella larvae: A promising animal model to study biofilm maturation in orthopedic infections

Meeting Abstract

  • presenting/speaker Raphaëlle Youf - Uniklinikum, Unfallchirurgie, Regensburg, Germany
  • Ruth Schewior - Uniklinikum, Unfallchirurgie, Regensburg, Germany
  • Gopala Mannala - Uniklinikum, Unfallchirurgie, Regensburg, Germany
  • You Zhao - Uniklinikum, Unfallchirurgie, Regensburg, Germany
  • Martijn Riool - Uniklinikum, Unfallchirurgie, Regensburg, Germany
  • Volker Alt - Universitätsklinikum Regensburg, Klinik und Poliklinik für Unfallchirurgie, Regensburg, Germany

Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2024). Berlin, 22.-25.10.2024. Düsseldorf: German Medical Science GMS Publishing House; 2024. DocAB90-2937

doi: 10.3205/24dkou513, urn:nbn:de:0183-24dkou5138

Published: October 21, 2024

© 2024 Youf et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Objectives: In trauma surgery, the development of biomaterial-associated infections (BAI) is one of the most common complications affecting trauma patients, requiring prolonged hospitalization and the intensive use of antibiotics. Following the attachment of bacteria on the surface of the biomaterial, the biofilm-forming bacteria could initiate a chronic implant-related infection. Despite the use of conventional local and systemic antibiotic therapies, persistent biofilms involve various resistance mechanisms that contribute to therapeutic failures. The development of in vivo chronic BAI models to optimize antibiofilm treatments is a major challenge. Indeed, the biofilm pathogenicity and the host response need to be finely regulated, and compatible with the animal lifestyle. Previously, a Galleria mellonnella larvae model for the formation of an early-stage biofilm on the surface of a Kirschner (K)-wire was established. In the present study, two models of mature biofilm using clinical Staphylococcus aureus strains were assessed: one related to contaminated k-wires (in vitro biofilm maturation) and the second to hematogenous infections (in vivo biofilm maturation). Rifampicin (80 mg/kg) was used as a standard drug for antibiofilm treatment.

Methods: In the first model, biofilms were formed following an incubation period (up to 7 days) in a CDC Biofilm Reactor (CBR, BioSurface Technologies). Then, after implantation of the pre-incubated K-wire in the larvae, rifampicin was injected and the larvae survival was monitored. In the second model, biofilm formation was achieved after an incubation period (up to 7 days) inside the larvae and then, after removing the K-wires from the host, in vitro rifampicin susceptibility assays were performed (EUCAST).

Results and conclusion: The first model indicate that in vitro biofilm maturation affects the bacterial pathogenicity in the host, depending on the S. aureus strain. Futhermore, more the biofilm is mature; more rifampicin treatment efficiency is compromised. The second model shows that, despite the fast in vivo biofilm formation time in the host, the number of bacteria attached to the k-wire surface and in the larvae tissues were not increasing over time. Altogether, these results allow the establishment of biofilm models using G. mellonella larvae in order to understand the impact of biofilm maturation on both the bacterial pathogenicity and the efficiency of antibiofilm treatments.